European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – December 2026, Online, from 9 December 2026, 09:30 (CET) to 9 December 2026, 10:30 (CET)

Submitted by Anonymous (not verified) on 5 November 2026 - 16:23

PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – December 2026, Online, from 9 December 2026, 09:30 (CET) to 9 December 2026, 10:30 (CET)

Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn

Submitted by Anonymous (not verified) on 5 November 2026 - 15:00

Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn

Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Date of authorisation: 22/12/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 5 November 2026 - 14:45

Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Date of authorisation: 22/12/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 24, Status: Authorised

Submitted by Anonymous (not verified) on 5 November 2026 - 14:14

Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 44, Status: Authorised

Submitted by Anonymous (not verified) on 5 November 2026 - 14:06

Human medicines European public assessment report (EPAR): Cosentyx, secukinumab, Date of authorisation: 14/01/2015, Revision: 44, Status: Authorised

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 5 November 2026 - 13:15

Human medicines European public assessment report (EPAR): Ogsiveo, nirogacestat, Date of authorisation: 14/08/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Jyseleca, filgotinib, Date of authorisation: 24/09/2020, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 5 November 2026 - 13:06

Human medicines European public assessment report (EPAR): Jyseleca, filgotinib, Date of authorisation: 24/09/2020, Revision: 15, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More